Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Obrindatamab · MGD-009

Bispecific antibody · Immune activation, directed at B7-H3 (CD276) (CD276) and CD3 (CD3E) · developed by MacroGenics

Phase 1 Most advanced trial (none active)
MGNX Developer
2 Registered trials

What is Obrindatamab?

Obrindatamab (MGD009, orlotamab) is an Fc-bearing humanized dual-affinity re-targeting (DART) bispecific protein that binds B7-H3 on tumor cells and CD3 on T cells. By cross-linking these cells, it redirects endogenous T cells to kill B7-H3-expressing tumor cells. It is studied in solid tumors including mesothelioma, bladder cancer, melanoma, lung cancer, ovarian cancer, and prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
MGD-009, orlotamab
Drug type
Bispecific antibody
Targets
B7-H3 (CD276) (CD276), CD3 (CD3E)
Mechanism
Immune activation, directed at B7-H3 (CD276) (CD276) and CD3 (CD3E)
Pathways
T-cell activation, T-cell redirected tumor cell killing, inhibition of tumor cell proliferation
Therapy area
Oncology
Developer
MacroGenics (MGNX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
YE8XXF1SDZ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03406949 Phase 1 Advanced Solid Tumors Completed MGNX
NCT02628535 Phase 1 Mesothelioma Terminated MGNX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorsBladder CancerBreast CancerClear Cell Renal Cell CarcinomaColon CancerMelanomaMesotheliomaNon Small Cell Lung CancerOvarian CancerPancreatic CancerProstate CancerSoft Tissue SarcomaSquamous Cell Carcinoma of the Head and NeckThyroid Cancer

Other drugs acting on CD276 / CD3E

More from MacroGenics

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the MGNX page.

Follow MGNX, the company behind Obrindatamab

See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MGNX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.